184 related articles for article (PubMed ID: 26034659)
1. Women's preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique.
Ralph AF; Ager B; Bell ML; Collins IM; Andrews L; Tucker K; O'Reilly N; Phillips KA; Butow P
Springerplus; 2014; 3():264. PubMed ID: 26034659
[TBL] [Abstract][Full Text] [Related]
2. Women's preferences for selective estrogen reuptake modulators: an investigation using protection motivation theory.
Ralph AF; Ager B; Bell ML; Collins IM; Andrews L; Tucker K; Phillips KA; Butow P
Patient Educ Couns; 2014 Jul; 96(1):106-12. PubMed ID: 24856850
[TBL] [Abstract][Full Text] [Related]
3. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
4. Decision making in the context of breast cancer chemoprevention: patient perceptions and the meaning of risk.
Holmberg C
Am Soc Clin Oncol Educ Book; 2015; ():e59-64. PubMed ID: 25993227
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
6. Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study.
Karavites LC; Allu S; Khan SA; Kaiser K
BMC Cancer; 2015 Nov; 15():878. PubMed ID: 26552376
[TBL] [Abstract][Full Text] [Related]
7. The selective estrogen receptor modulators in breast cancer prevention.
Li F; Dou J; Wei L; Li S; Liu J
Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
[TBL] [Abstract][Full Text] [Related]
8. Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?
Tesson S; Richards I; Porter D; Phillips KA; Rankin N; Costa D; Musiello T; Marven M; Butow P
Breast; 2017 Feb; 31():233-240. PubMed ID: 27969575
[TBL] [Abstract][Full Text] [Related]
9. Current concepts in breast cancer chemoprevention.
Chlebowski RT
Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912
[TBL] [Abstract][Full Text] [Related]
10. Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.
Crew KD
Am Soc Clin Oncol Educ Book; 2015; ():e50-8. PubMed ID: 25993215
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of breast cancer with selective estrogen receptor modulators: views from broadly diverse focus groups of women with elevated risk for breast cancer.
Cyrus-David MS; Strom SS
Psychooncology; 2001; 10(6):521-33. PubMed ID: 11747064
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
Dhingra K
Cancer Invest; 2001; 19(6):649-59. PubMed ID: 11486708
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with intentions for breast cancer risk management: Does risk group matter?
Conley CC; Agnese DM; Vadaparampil ST; Andersen BL
Psychooncology; 2019 May; 28(5):1119-1126. PubMed ID: 30889627
[TBL] [Abstract][Full Text] [Related]
14. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
15. [Effect of selective estrogen receptor modulators on estrogen-sensitive tissues].
Jirecek S; Pavo I; Huber JC
Gynakol Geburtshilfliche Rundsch; 1999; 39(4):184-90. PubMed ID: 10629380
[TBL] [Abstract][Full Text] [Related]
16. NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction.
Holmberg C; Bandos H; Fagerlin A; Bevers TB; Battaglia TA; Wickerham DL; McCaskill-Stevens WJ
Cancer Prev Res (Phila); 2017 Nov; 10(11):625-634. PubMed ID: 28978566
[TBL] [Abstract][Full Text] [Related]
17. [Selective Estrogen Receptor Modulators (SERMs) for prevention and treatment of postmenopausal osteoporosis].
Birkhäuser M
Ther Umsch; 2012 Mar; 69(3):163-72. PubMed ID: 22403109
[TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptor modulators (SERMs): a review of clinical data.
Mirkin S; Pickar JH
Maturitas; 2015 Jan; 80(1):52-7. PubMed ID: 25466304
[TBL] [Abstract][Full Text] [Related]
19. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).
Musa MA; Khan MO; Cooperwood JS
Curr Med Chem; 2007; 14(11):1249-61. PubMed ID: 17504144
[TBL] [Abstract][Full Text] [Related]
20. Use of SERMs for treatment in postmenopausal women.
Pinkerton JV; Thomas S
J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
